Skip to main content
English Cymraeg

Novel and non-traditional foods, additives and processes

What is the impact and risk of novel and non-traditional foods, additives, and processes on the food system, including on consumer confidence?

Food innovation and use of new foods and technological developments have the potential to add variety to our diets and address some of the challenges facing the food production system today. As these foods and feeds have not been eaten before there is a need to understand the impact of these new products or technologies to ensure consumers have access to safe food innovation. 

The overarching aim of this Area of Research Interest (ARI) is to understand the impact of these regulated products and emerging food innovations on the UK consumer.  

The major aims of this ARI include:  

  • Building our scientific understanding of new food products, processes and innovations. 
  •  
  • Exploring detection techniques to understand the nature of these products and to provide support for enforcement as needed.  
  •  
  • Employing social science methodologies to assess consumer acceptance and uptake of food innovations. 

This ARI contributes to the wider work of the FSA on products that require premarket review to ensure any food safety issues are managed. This ARI also adds to the evidence base to understand new foods, food ingredients or feed additives that are near market so these can be assessed in a proportionate way.

Important
From 1 August 2024 we publish reports in this area of research interest (ARIs) on our dedicated FSA Research and Evidence platform.

 

Research projects related to the programme

Novel Foods Regulatory Framework Review: Executive Summary

This Executive Summary has been prepared for FSA’s exclusive use and the sole purpose of providing to the FSA a summary in connection with informing FSA and commenting on the existing Novel Foods Framework. Deloitte is responsible solely to the FSA for the work performed. No party is entitled to rely on this Executive Summary for any purpose and Deloitte accepts no responsibility or liability or duty of care to any party whatsoever in respect of the contents of this Executive Summary.